A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury

被引：270

作者：

Singer, Jonathan B. ^{[1
]}

Lewitzky, Steve ^{[1
]}

Leroy, Elisabeth ^{[1
]}

Yang, Fan ^{[1
]}

Zhao, Xiaojun ^{[1
]}

Klickstein, Lloyd ^{[1
]}

Wright, Timothy M. ^{[1
]}

Meyer, Joanne ^{[1
]}

Paulding, Charles A. ^{[1
]}

机构：

[1] Novartis Inst BioMed Res, Cambridge, MA USA

来源：

NATURE GENETICS | 2010年 / 42卷 / 08期

关键词：

THERAPEUTIC ARTHRITIS RESEARCH; RANDOMIZED CONTROLLED-TRIAL; HYPERSENSITIVITY; HEPATOTOXICITY; ABACAVIR; EVENT; HLA-B-ASTERISK-5701; OSTEOARTHRITIS; PATHOGENESIS; IBUPROFEN;

D O I：

10.1038/ng.632

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Lumiracoxib is a selective cyclooxygenase-2 inhibitor developed for the symptomatic treatment of osteoarthritis and acute pain(1). Concerns over hepatotoxicity have contributed to the withdrawal or non-approval of lumiracoxib in most major drug markets worldwide. We performed a case-control genome-wide association study on 41 lumiracoxib-treated patients with liver injury (cases) and 176 matched lumiracoxib-treated patients without liver injury (controls). Several SNPs from the MHC class II region showed strong evidence of association (the top SNP was rs9270986 with P = 2.8 x 10(-10)). These findings were replicated in an independent set of 98 lumiracoxib-treated cases and 405 matched lumiracoxib-treated controls (top SNP rs3129900, P = 4.4 x 10(-12)). Fine mapping identified a strong association to a common HLA haplotype (HLA-DRB1*1501-HLA-DQB1*0602-HLADRB5*0101-HLA-DQA1*0102, most significant allele P = 6.8 x 10(-25), allelic odds ratio = 5.0, 95% CI 3.6-7.0). These results offer the potential to improve the safety profile of lumiracoxib by identifying individuals at elevated risk for liver injury and excluding them from lumiracoxib treatment.

引用

页码：711 / U94

页数：6

共 21 条

[1] Lumiracoxib in the management of osteoarthritis and acute pain [J].

Bannwarth, Bernard ;

Berenbaum, Francis .

EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (10) :1551-1564

[2]

Center for Drug Evaluation and Research (CDER) in cooperation with the Center for Biologics Evaluation and Research (CBER) and the Center for Devices and Radiological Health (CDRH) at the Food and Drug Administration (FDA) Guidance for industry, 2009, PATIENT REPORTED OUT

[3] A marker for Stevens-Johnson syndrome [J].

Chung, WH ;

Hung, SI ;

Hong, HS ;

Hsih, MS ;

Yang, LC ;

Ho, HC ;

Wu, JY ;

Chen, YT .

NATURE, 2004, 428 (6982) :486-486

[4] HLA-B☆5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin [J].

Daly, Ann K. ;

Donaldson, Peter T. ;

Bhatnagar, Pallav ;

Shen, Yufeng ;

Pe'er, Itsik ;

Floratos, Aris ;

Daly, Mark J. ;

Goldstein, David B. ;

John, Sally ;

Nelson, Matthew R. ;

Graham, Julia ;

Park, B. Kevin ;

Dillon, John F. ;

Bernal, William ;

Cordell, Heather J. ;

Pirmohamed, Munir ;

Aithal, Guruprasad P. ;

Day, Christopher P. .

NATURE GENETICS, 2009, 41 (07) :816-U71

[5] Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial [J].

Farkouh, ME ;

Kirshner, H ;

Harrington, RA ;

Ruland, S ;

Verheugt, FW ;

Schnitzer, T ;

Burmester, GR ;

Mysler, E ;

Hochberg, MC ;

Doherty, M ;

Ehrsam, E ;

Gitton, X ;

Krammer, G ;

Mellein, B ;

Gimona, A ;

Matchaba, P ;

Hawkey, CJ ;

Chesebro, JH .

LANCET, 2004, 364 (9435) :675-684

[6] HLA association of amoxicillin-clavulanate-induced hepatitis [J].

Hautekeete, ML ;

Horsmans, Y ;

van Waeyenberge, C ;

Demanet, C ;

Henrion, J ;

Verbist, L ;

Brenard, R ;

Sempoux, C ;

Michielsen, PP ;

Yap, PSH ;

Rahier, J ;

Geubel, AP .

GASTROENTEROLOGY, 1999, 117 (05) :1181-1186

[7] Genetic variations in HLA-B region and hypersensitivity reactions to abacavir [J].

Hetherington, S ;

Hughes, AR ;

Mosteller, M ;

Shortino, D ;

Baker, KL ;

Spreen, W ;

Lai, E ;

Davies, K ;

Handley, A ;

Dow, DJ ;

Fling, ME ;

Stocum, M ;

Bowman, C ;

Thurmond, LM ;

Roses, AD .

LANCET, 2002, 359 (9312) :1121-1122

[8] Idiosyncratic drug hepatotoxicity [J].

Kaplowitz, N .

NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (06) :489-499

[9] Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis [J].

Kindmark, A. ;

Jawaid, A. ;

Harbron, C. G. ;

Barratt, B. J. ;

Bengtsson, O. F. ;

Andersson, T. B. ;

Carlsson, S. ;

Cederbrant, K. E. ;

Gibson, N. J. ;

Armstrong, M. ;

Lagerstrom-Fermer, M. E. ;

Dellsen, A. ;

Brown, E. M. ;

Thornton, M. ;

Dukes, C. ;

Jenkins, S. C. ;

Firth, M. A. ;

Harrod, G. O. ;

Pinel, T. H. ;

Billing-Clason, S. M. E. ;

Cardon, L. R. ;

March, R. E. .

PHARMACOGENOMICS JOURNAL, 2008, 8 (03) :186-195

[10] Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir [J].

Mallal, S ;

Nolan, D ;

Witt, C ;

Masel, G ;

Martin, AM ;

Moore, C ;

Sayer, D ;

Castley, A ;

Mamotte, C ;

Maxwell, D ;

James, I ;

Christiansen, FT .

LANCET, 2002, 359 (9308) :727-732

← 1 2 3 →